Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01707290 · ClinicalTrials.gov registry record · Phase 3

Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation

A Phase 3 study of Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated.

Completed
Registry status
Phase 3
Development phase
125
Enrollment target
20
Study locations

NCT01707290 is a Phase 3 study of Cystic Fibrosis that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 125 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (30% lower). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01707290, a Phase 3 study of Cystic Fibrosis, has completed, sponsored by Vertex Pharmaceuticals Incorporated.

COMPLETED
Registry status
Phase 3
Development phase
125 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the safety of long-term ivacaftor treatment in participants with cystic fibrosis (CF) from Studies 110 (NCT01614457), 111 (NCT01614470), and 113 (NCT01685801).

Conditions Studied

Cystic Fibrosis

Interventions

  • DRUG Ivacaftor

Study Locations (20)

Michigan

  • - Ann Arbor
  • - Detroit
  • - Grand Rapids

New York

  • - New York
  • - Syracuse
  • - Valhalla

Alabama

  • - Birmingham

California

  • - Palo Alto

Colorado

  • - Denver

Connecticut

  • - Hartford

Florida

  • - Tampa

Georgia

  • - Atlanta

Trial Details

FieldValue
Enrollment Target 125 participants
Start Date 2013-02
Est. Completion 2016-04
Phase Phase 3

Sponsor

Vertex Pharmaceuticals Incorporated

191 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01707290

The ClinicalTrials.gov registry entry for NCT01707290 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (30% lower). The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which Ivacaftor is the first listed.

NCT01707290 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Michigan, New York, Alabama.

Frequently Asked Questions

What is clinical trial NCT01707290 about?

NCT01707290 is a clinical study titled "Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation". The purpose of this study is to evaluate the safety of long-term ivacaftor treatment in participants with cystic fibrosis (CF) from Studies 110 (NCT01614457), 111 (NCT01614470), and 113 (NCT01685801).

What is the current status of trial NCT01707290?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 125 participants. The study started on 2013-02. Estimated completion is 2016-04.

What conditions does trial NCT01707290 study?

This clinical trial studies the following conditions: Cystic Fibrosis.

What interventions are being tested in trial NCT01707290?

The interventions under investigation include: Ivacaftor (DRUG).

Who is sponsoring clinical trial NCT01707290?

This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01707290 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cystic Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cystic Fibrosis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.